Search

Issue
Title
Authors
Efficacy of second autologous stem cell transplantation in patients with multiple myeloma
Mendeleeva L.P., Irugova E.Z., Solovev M.V., Soloveva M.V., Klyasova G.A., Startsev A.A., Starchenko S.E., Kulikov S.M.
Efficacy of daratumumab as monotherapy or in combination with antitumor drugs in patients with relapsed / refractory multiple myeloma depending on the previous chemotherapy lines number
Belousov K.A., Mitina T.A., Trifonova E.V., Chernykh Y.B., Zakharov S.G., Kataeva E.V., Vysotskaya L.L., Kharasova Z.M., Vardanyan R.V., Madzyara O.P., Voroshkevich A.A.
Kidney damage in patients with multiple myeloma associated with light chain deposition disease and C3 glomerulopathy
Popova A.V., Solovev M.V., Arutyunyan N.K., Soloveva M.V., Rekhtina I.G., Mendeleeva L.P.
Multiple myeloma: a retrospective analysis of clinical outcomes based on the patient registry of the Moscow City Clinical Hospital No. 52 (2022–2025)
Misyurina E.N., Zotina E.N., Gadzhieva S.M., Chernova N.G., Karimova E.A., Zhelnova E.I., Baryakh E.A., Makeshova A.B., Maryin D.S., Zakharov O.D., Tolstykh T.N., Yakimets V.N., Grishina E.Y., Mingalimov M.A., Chudnova T.S., Polyakov D.S., Badaev R.S., Khordzhasov L.O., Zinchuk A.A., Kondratev V.I., Kochneva O.L., Ivanova D.D., Shimanovskaya L.T., Lebedev D.V., Sarakaeva Z.T., Savosina N.A., Yatskov K.V., Mamaeva E.A., Makunina E.A., Orlova M.S., Lysenko M.A., Kotenko O.N., Frolova N.F., Rukavitsyn O.A., Nekrasova A.V., Semina T.A., Lysenko M.A.
KRAS, NRAS, BRAF genes mutations in tumor cells of various localizations and their impact on the treatment outcomes of patients with multiple myeloma
Soloveva M.V., Solovev M.V., Yakutik I.A., Biderman B.V., Popova A.V., Risinskaya N.V., Nikulina E.E., Obukhova T.N., Sudarikov A.B., Mendeleeva L.P.
Proteasome inhibitors: situation and prospects (literature review and own data)
Rukavitsyn A.A., Rukavitsyn O.A.
Pomalidomide for the management of relapsed and refractory multiple myeloma: a case report and review of literature
Semochkin S.V.
Plasma cell dyscrasia: monoclonal gammopathies, AL-amyloidosis, multiple myeloma Clinical case study
Cherepanova V.V., Kurysheva M.A., Odintsova S.V.
Pain syndrome in multiple myeloma (results of a single-center study)
Soloveva M.V., Solovev M.V., Irugova E.Z., Startsev A.A., Arutyunyan N.K., Krayzman A.A., Abakumova A.V., Mendeleeva L.P.
Clinical case of giant extramedullar plasmacytoma in a patient with multiple myeloma
Safuanova G.S., Mansurova Y.R., Latypova A.A., Bagautdinova А.U., Rozhenkova T.Y., Valiakhmetova C.K.
Modern strategies in therapy of elderly patients with multiple myeloma
Bessmeltsev S.S., Stelmashenko L.V., Kariagina E.V., Stepanova N.V., Salogub G.N., Shelkovskaya T.L., Malakhova T.A., Skorokhod I.A., Podoltseva E.I., Saraeva N.O., Kovalev O.I., Klimovich A.V., Medvedeva N.V., Abdulkadyrov K.M., Krylova L.I., Potrachkova T.H., Novikova M.A., Machulaitene E.R., Darskaya E.I., Matukhina L.M., Kotova N.A., Kostina O.Y., Novokreshchenova I.A.
Bortezomib neurotoxicity treatment of multiple myeloma: single center experience and literature review
Stepanova N.V., Machulaitene E.R., Salogub G.N., Melnikova E.V.
Neutrophilic hyperleukocytosis in the multiple myeloma onset
Rekhtina I.G., Kolosova L.Y., Khyshova V.A., Kovrigina A.M., Mendeleeva L.P.
Features of 18F-fluorodeoxyglucose uptake in multiple myeloma
Subbotin A.S., Pronin A.I., Odzharova A.A., Komarova M.A.
The late extramedullary relapse of the multiple myeloma with a predominant lesion of the duodenum and pancreas (clinical observation and mini-review)
Rukavitsyn O.A., Kryukov E.V., Troyan V.N., Kozyrev S.V., Pop V.P., Pravosudov V.V., Simashova P.I., Drozd M.V., Popkov Y.Е., Alekseev S.A., Sapelnikova E.R.
REACTIVE PLASMACYTOSIS AT THE ONSET OF ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA. CASE REPORT
Chernova N.G., Sinitsyna M.N., Kovrigina A.M., Sidorova Y.V., Galtseva I.V., Mar’ina S.A., Dvirnyk V.N., Zvonkov E.E.
Chronic lymphoproliferative diseases: survival in cohort study of 310 patients (single-center study results and literature data)
Pop V.P., Rukavitsyn O.A.
Autologous stem cell transplantation in newly diagnosed multiple myeloma patients with severe renal failure requiring hemodialysis. A single-center experience
Kliuchagina Y.I., Zeynalova P.A., Gromova E.G., Valiev T.T.
Case report: pomalidomide as maintenance after salvage autologous stem cell transplantation in a patient with relapsed multiple myeloma
Semochkin S.V., Lunin V.V., Vernyuk М.А., Fedenko А.А.
Osteodestruction markers and quality of life parameters at pomegara (pamidronate) treatment in multiple myeloma patients with lytic bone lesions
Lunin V.V., Yurova Y.V., Kudryavtseva O.A., Minenko S.V., Ptushkin V.V.
Treatment of bone complications in multiple myeloma patients
Ptushkin V.V.
Pomalidomide in relapsed and refractory multiple myeloma: multicenter retrospective study
Potapenko V.G., Baumert E.V., Bobrova A.A., Vashchenkov R.V., Dorofeeva N.V., Kaplanov K.D., Karyagina E.V., Levanov A.N., Luchinin A.S., Moiseev S.I., Novitskii A.V., Nizamutdinova A.S., Pirogova О.V., Povzun S.A., Platonov М.V., Porunova V.V., Ptashnikov D.А., Ryabchikova V.V., Simeniv S.Y., Skorokhod I.А., Ukrainchenko Е.А., Chaginskaya D.А., Shelekhova T.V., Shirokova M.N., Shutylev A.A., Medvedeva N.V.
The role of bone marrow microenvironment in the progression of multiple myeloma from monoclonal gammopathy of undetermined significance
Khudovekova A.S., Rudenko Y.A., Dorosevich A.E.
New proteasome inhibitors in the management of multiple myeloma
Semochkin S.V.
EPIDEMIOLOGY OF MULTIPLE MYELOMA ACCORDING TO THE КIROV REGION POPULATION REGISTERS
Luchinin A.S., Semochkin S.V., Minaeva N.V., Pozdeev N.M., Paramonov I.V.
Patogenetic correction of anemia with erythropoiesis-stimulating agents in lymphoproliferative disorders (literature review)
Romanenko N.A., Abdulkadyrov K.M.
Adherence to treatment in patients with multiple myeloma and pain syndrome
Vybornykh D.E., Irugova Z.E., Esina L.V., Fedorova S.Y., Solov’ev M.V., Solov’eva M.V., Mendeleeva L.P.
Very good partial remission predicts progression-free survival in patients with multiple myeloma
Luchinin A.S., Semochkin S.V.
Role of high-dose chemotherapy with hemopoietic stem cell transplantation in the treatment of multiple myeloma
Minenko S.V., Popov A.Y., Zhukov N.V., Votyakova O.M., Ptushkin V.V.
Bortezomib (Velcade) in combination with dexamethasone eor relapsed or refractory myeloma
Bessmeltsev S.S., Stelmashenko L.V., Podoltseva E.I., Kariagina E.V., Salogub G.N., Nisamutdinova А.S., Matuhina L.M., Abdulkadyrov K.M.
Prevention and management of bortezomib-induced peripheral neuropathy in patients with multiple myeloma
Semochkin S.V., Solovyev M.V., Mendeleeva L.P.
Flow cytometry in the diagnosis of plasma cell tumors and assessment of minimal residual disease
Grivtsova L.Y., Mushkarina T.Y., Lunin V.V., Zeynalova P.A.
The experience of free light chains of immunoglobulin elimination in patients with monoclonal gammopathies
Gromova E.G., Zeynalova P.A., Lubimova N.V., Timofeev Y.S., Kushlinskiy N.E., Semenova A.A., Lunin V.V., Kluchagina Y.I.
FLOW CYTOMETRY IN THE DIAGNOSIS AND MONITORING OF MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA
Galtseva I.V., Davydova Y.O., Kapranov N.M., Julakyan U.L., Mendeleeva L.P.
Herpes zoster in multiple myeloma patients during bortezomib treatment
Nazarova I.N., Protasova M.N., Nikishina N.A.
c-MAF protein expression in multiple myeloma
Solov’eva M.V., Solov’ev M.V., Melnikova M.V., Kovrigina A.M., Obukhova T.N., Mendeleeva L.P.
Clinical features and treatment strategy for patients with multiple myeloma during the COVID-19 pandemic
Yakimets V.N., Misyurina E.N., Zhelnova E.I., Baryakh E.A., Yatskov K.V., Makeshova A.B., Karimova E.A., Zotina E.N., Grishina E.Y., Gagloeva D.E., Mingalimov M.A., Tolstykh T.N., Chudnova T.S., Kochneva O.L., Shimanovskaya L.T., Polyakov Y.Y.
Specifics of the telemedicine in patients with paraproteinemic hemoblastoses
Soloveva M.V., Solovev M.V., Mendeleeva L.P.
PRAME, WT1 and XIAP tumor-associated genes expression in multiple myeloma patients
Gaponova T.V., Mendeleeva L.P., Misurin A.V., Varlamova E.V., Savchenko V.G.
The use of non-cryopreserved hematopoietic stem cells for autologous transplantation in multiple myeloma patients
Voloshin S.V., Garifullin A.D., Kuzyaeva A.A., Sinitsina N.N., Alekseeva N.N., Schmidt A.V., Linnikov S.Y., Shuvaev V.A., Kuvshinov A.Y., Potikhonova N.A., Seltser A.V., Balashova V.A., Chubukina Z.V., Bogdanov A.N., Sidorkevich S.V.
Differences in interactions with the bone microenvironment between solid tumors and multiple myeloma: pathogenetic aspects. Possibilities and effectiveness of osteomodifying agents in multiple myeloma
Snegovoy A.V., Larionova V.B., Kononenko I.B.
Efficiency of lenalidomide, bortezomib and prednisone (RVP) in patients with newly diagnosed multiple myeloma
Belousov K.A., Mitina T.A., Chuksina Y.Y., Golenkov A.K., Kataeva E.V., Trifonova E.V., Chernykh Y.B., Vysotskaya L.L., Zakharov S.G., Klinushkina E.F., Mitin A.N.
STUDY OF MINIMAL RESIDUAL DISEASE BY MULTICOLOR FLOW CYTOMETRY IN MULTIPLE MYELOMA AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
Galtseva I.V., Mendeleeva L.P., Davydova Y.O., Solov’ev M.V., Kapranov N.M., Kuzmina L.A., Gribanova E.O., Gaponova T.V., Savchenko V.G.
Lenalidomide for relapsed or refractory multiple myeloma
Bessmeltsev1 S.S., Kariagina E.V., Stelmashenko L.V., Salogub G.N., Machulaitene E.R., Abdulkadyrov K.M., Kotova N.A., Kostroma I.I., Medvedeva N.V., Krylova L.I., Ilushkina E.Y.
Bortezomib-induced peripheral neuropathy in patients with multiple myeloma: pain syndrome and psychopathological aspects
Irugova E.Z., Mendeleeva L.P., Vybornykh D.E., Soloveva M.V., Fedorova S.Y., Solovev M.V.
Coronavirus infection after blood stem cell transplantation
Grishina E.Y., Misyurina E.N., Zhelnova E.I., Baryakh E.A., Yatskov K.V., Makeshova A.B., Karimova E.A., Zotina E.N., Gagloeva D.E., Yakimets V.N., Mingalimov M.A., Tolstykh T.N., Polyakov Y.Y., Chudnova T.S., Kochneva O.L., Shimanovskaya L.T.
Significance of bone marrow immunohistochemical analysis in patients with plasma cell neoplasms
Kozich Z.M., Martinkov V.N., Zhandarov M.Y., Pugacheva Z.N., Klimkovich N.N.
Results of multiple myeloma treatment with bortezomib
Pospelova T.I., Skvortzova N.V., Nechunaeva I.N.
Pitfalls in the pathological diagnosis of multiple myeloma
Baykov V.V.
MAGE-C1 gene and mage-c1 protein expression comparison in primary multiple myeloma patients
Makunina E.A., Mendeleeva L.P., Surin V.L., Soloviev M.V., Firsova M.V., Kovrigina A.M., Sherstnev A.A., Gal’tseva I.V., Davydova Y.O., Kulikov S.M.
Cancer-testis antigen MAGE-C1/ CT7 in multiple myeloma: literature review
Makunina E.A.
Efficiency of pomalidomide therapy in patients with multiple myeloma refractory to lenalidomide
Rekhtina I.G., Mendeleeva L.P.
Correction of anemia in multiple myeloma patients by erythropoiesis-stimulating agents
Romanenko N.A., Potikhonova N.A., Abdulkadyrov K.M.
Netupitant / palonosetron with dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous hematopoietic stem cell transplantation: a single-center experience
Mochkin N.E., Shorokhov N.S., Sarzhevskiy V.O., Bogatyrev V.S., Samoylova A.A., Rukavitsyn A.A., Smirnova E.G., Bannikova A.E., Mamedova A.A., Protopopova Y.V., Melnichenko V.Y.
Basic therapeutic approaches to the management of hematology/oncology patients with new coronavirus infection (COVID-19)
Misyurina E.N., Baryakh E.A., Frolova N.F., Kotenko O.N., Mutovina Z.Y., Andreev S.S., Tolstykh T.N., Yatskov K.V., Karimova E.A., Makeshova A.B., Rukavitsyn O.A., Misyurin A.V., Polyakov Y.Y., Mingalimov M.A., Chudnova T.S., Gagloeva D.E., Ivanova D.D., Koneva A.I., Kochneva O.L., Zotina E.N., Grishina E.Y., Shimanovskaya L.T., Yakimets V.N., Zhelnova E.I.
Influence of TNF-alpha on the efficacy of anemia correction in patients with lymphoproliferative disorders
Romanenko N.A., Bessmeltsev S.S., Rozanova O.E., Karpova N.S., Abdulkadyrov K.M.
Eprex in the management of anemia related to lymphoproliferative disorders
Barlamov P.N., Golubeva M.E., Firsova G.V., Vasilyeva E.R., Meresiy S.V., Kanukova O.V., Klimova I.V., Shutilev A.A., Avtomenko M.A., Shekotov V.V., Zaychykina U.V.
Informative value of whole-body magnetic resonance imaging with diffusion-weighted images for the detection of bone marrow infiltration in patients with multiple myeloma (literature review)
Lutsik N.S., Mendeleeva L.P., Yatsik G.A.
Prognostic value of the modified multiple myeloma comorbidity index in real clinical practice
Skvortsova N.V., Kovynev I.B., Loginova A.B., Halzov K.V., Pospelova T.I.
Bone marrow MRI after autologous transplantation and the effect of residual tumor on progression-free survival of multiple myeloma patients
Solovev M.V., Mendeleeva L.P., Yatsyk G.A., Lutsik N.S., Firsova M.V., Gemdzhian E.G., Savchenko V.G.
Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma
Мitinа T.A., Golenkov A.K., Trifonova E.V., Kataeva E.V., Vysotskaya L.L., Chernykh Y.B., Zakharov S.G., Belousov K.A., Karaulov A.V.
Pathogenesis and therapy of anemia in oncohemathology patients with recombinant erythropoietin agents (review)
Romanenko N.A.
Successful experience of venetoclax in the treatment of refractory primary plasma cell leukemia
Cherkashina I.V., Vernyuk M.A., Semochkin S.V., Khayrullina L.S., Chervontseva A.M., Smirnova T.Y., Kosumova K.S., Fedenko A.A.
Isatuximab in the treatment of refractory and relapsed multiple myeloma: literature review and case report
Ryabukhina Y.E., Zeynalova P.A., Abbasbeyli F.M., Timofeeva O.L., Valiev T.T., Kupryshina N.A., Zhukov A.G.
Clinical features of multiple myeloma with bone plasmacytomas
Mamaeva E.A., Soloveva M.V., Solovev M.V., Kovrigina A.M., Danilina T.P., Mendeleeva L.P.
Incidence, characteristics, and treatments of peripheral neuropathy in multiple myeloma patients receiving bortezomib (velcade)
Bessmeltsev S.S., Karyagina E.V., Stelmashenko L.V., Stepanova N.V., Machulaiten E.R., Salogub G.N., Skorokhod I.A., Medvedeva N.V., Podoltseva E.I., Matyukhina L.M., Nizamutdinova A.S., Abdulkadyrov K.M.
Biological basis of immunomodulatory preparations using in treatment of multiple myeloma
Semochkin S.V.
The role of pomalidomide in treatment of relapse and refractory multiple myeloma
Voloshin S.V., Linnikov S.Y., Garifullin A.D., Kuzyaeva A.A., Shmidt A.V., Kuvshinov A.Y., Bogdanov A.N., Mikhileva M.A., Martynkevich I.S., Zenina M.N., Sidorkevich S.V.
The importance of serum immunoglobulin free light chain assessment for predicting outcome in patients with newly diagnosed multiple myeloma in real clinical practice
Skvortsova N.V., Kovynev I.B., Halzov K.V., Pospelova T.I.
Infectious complications in patients with multiple myeloma on first chemotherapy cycle
Novikova A.A., Klyasova G.A., Gribanova E.O., Okhmat V.A., Ryzhko V.V., Savchenko V.G.
Therapy efficacy in multiple myeloma patients received autologous stem cells transplantation as first line therapy
Darskaya Y.I., Marami-Zonuzi N.E., Osipov Y.S., Estrina M.A., Babenko Y.V., Vavilov V.N., Afanasiev B.V.
Efficacy of IsaPomDex triplet therapy in double refractory multiple myeloma patients in real clinical practice in Russia
Solovev M.V., Solovevа M.V., Mendeleeva L.P., Pospelova T.I., Skvortsova N.V., Voloshin S.V., Garifullin A.D., Chuprakova A.S., Mitina T.A., Usankin I.S., Vasileva I.V., Medvedeva N.V., Ryabchikova V.V., Kiseleva M.Y., Dudina G.A., Gammershmidt Y.S., Kuznetsova O.S., Dolgushina Y.V., Kuchma G.B., Tsyganok T.N., Misyurina E.N., Zhelnova E.I., Kopylova A.V., Zakharova M.N., Korobkin A.V., Tumyan G.S., Semenova A.A., Kirillova E.G., Volodicheva E.M., Bakhtina V.I., Olkhovik T.I., Solovkova N.R., Demchenkova M.V., Ochirova O.E., Panteleeva O.L., Abramova V.S.
Elotuzumab in the treatment of patients with refractory and relapsed multiple myeloma Experience of the Lapino Clinical Hospital Oncohematology Department
Ryabukhina Y.E., Zeynalova P.A., Abbasbeyli F.M., Timofeeva O.L., Kupryshina N.A., Valiev T.T.
Combination of multiple myeloma and chronic idiopathic myelofibrosis: a case report
Romanenko N.A., Bessmeltsev S.S., Rugal V.I., Potichonova N.A., Zenina M.N., Abdulkadirov K.M.
Bortezomib (velcade) plus melphalan and prednisone in elderly untreated patients with multiple myeloma
Bessmeltsev S.S., Stelmashenko L.V., Stepanova N.V., Abdulkadyrov K.M., Salogub G.N., Machulaitene E.R., Kariagina E.V.
Multiple myeloma with extramedullary plasmacytoma: pathogenesis and clinical case
Firsova M.V., Risinskaya N.V., Solovev M.V., Obukhova T.N., Kislitsyna M.A., Nikulina E.E., Yakutik I.A., Abramova T.V., Sudarikov A.B., Kovrigina A.M., Mendeleeva L.P.
Treatment of double-refractory multiple myeloma
Semochkin S.V.
Long-term continuous treatment as a new strategy for relapsed or refractory multiple myeloma
Semochkin S.V.
MORPHOLOGICAL FEATURES OF TUMORS SUBSTRATE IN MULTIPLE MYELOMA PATIENTS COMPLICATED WITH PLASMACYTOMA
Firsova M.V., Mendeleeva L.P., Kovrigina A.M., Deyneko N.I., Soloviev M.V., Gemdzhyan E.G., Savchenko V.G.
The multicenter experience with bendamustine in the treatment of relapsed and refractory multiple myeloma
Voloshin S.V., Bessmeltsev S.S., Zagoskina T.P., Medvedeva N.V., Kaplanov K.D., Karyagina E.V., Garifullin A.D., Kuvshinov A.Y., Stelmashenko L.V., Abdulkadyrov K.M.
1 - 80 of 80 Items

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default only articles containing all terms in the query are returned (i.e., AND is implied)
  • Combine multiple words with OR to find articles containing either term; e.g., education OR research
  • Use parentheses to create more complex queries; e.g., archive ((journal OR conference) NOT theses)
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing"
  • Exclude a word by prefixing it with - or NOT; e.g. online -politics or online NOT politics
  • Use * in a term as a wildcard to match any sequence of characters; e.g., soci* morality would match documents containing "sociological" or "societal"

The website of the journal Oncohematology contains materials intended exclusively for healthcare professionals.

By closing this message, you confirm* that you are a licensed healthcare professional or a student of a medical educational institution.

This one-time confirmation is valid for the next 30 days.